The Alzheimer's Disease Therapeutics and Diagnostics World Market will Reach $7.0Bn in 2014, According to a New Study on ASDReports

Tuesday 30 September 2014, Amsterdam

A new report, now available on ASDReports, calculates that the Alzheimer’s Disease Therapeutics and Diagnostics market will reach $7.0bn in 2014 with revenue showing strong overall growth to 2024, particularly beyond 2018. These forecasts and others appear in Alzheimer’s Disease Therapeutics and Diagnostics Market Forecast 2014-2024: Opportunities for Leading Companies, published in August 2014.

The Alzheimer’s disease therapeutics world market has stagnated over the last few years because of the loss of patent protection of key drugs in major markets and the woeful lack of success in critical late phase clinical trials. A study has recently found that in the years 2002-2012, 99.6% of drug trials for Alzheimer’s have failed or been discontinued. Nevertheless, the reports analysts are optimistic that the three drug candidates such as solanezumab, MK-8931 and gantenrumab, which are reported to offer disease-modifying benefits, will be approved towards the second half of the forecast period and will drive the market to skyrocket in sales. Alzheimer’s diagnostics research has shown some more promising outcomes over the past few years. Diagnostic development has focused primarily on measuring levels of amyloid beta aggregates or tau proteins.

Amy To, a pharmaceutical and medical devices analyst explains:  “The incidence of Alzheimer’s has reached epidemic levels and has captured political consciousness owing to its immense socio-economic impact. Global initiatives to fuel the funding of research have been driven by the available medications falling far short of market needs. The development of Alzheimer’s diagnostics and therapeutics are inextricably linked, the arrival of disease-modifying drugs on the market will dramatically boost the Alzheimer’s diagnostic market, as patients will see the benefit of early diagnosis. The current mode of thinking is that the best chance of treating Alzheimer’s is at an early stage. Although new diagnostic biomarkers are predominately used for screening patients who can participate in research studies, the focus in the future is to find biomarkers that are both accurate enough and commercially viable to use in the hospital and clinical setting.”

The fastest growth will continue to be seen in the emerging economies, where there is still high growth in revenues of Alzheimer’s drugs that have gone off-patent in the majority of developed markets. China’s Alzheimer’s market has experienced double-digit growth over the last few years owing to the rapid expansion of health coverage in the country. Many leading Alzheimer’s therapeutic companies are investing aggressively to increase their presence in the country and this trend is set to continue with the demand from a rapidly ageing population.

The reports new 185 page report provides revenue forecasts to 2024 for the global Alzheimer’s disease therapeutics and diagnostics market and leading national markets. It forecasts sales in the US, Japan, Europe (EU5: Germany, France, Italy, Spain, UK and the rest of Europe), China, India, Russia, Brazil and Rest of the World. The report also forecasts sales for the major drugs in the Alzheimer’s therapeutic market, including revenue forecasts for promising drugs currently in late stages of development, and the submarkets in the Alzheimer’s diagnostics market. It also includes 3 insightful interviews with industry experts.

Alzheimer’s Disease Therapeutics and Diagnostics Market Forecast 2014-2024: Opportunities for Leading Companies adds to the reports range of analytical reports on industries and markets in healthcare.